


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claims 1 to 25 (*cancelled*)

26. (*previously presented*) A method of treating a subject suffering from a condition selected from the group consisting of neurodegenerative disease, eating disorders, disorders of thermoregulation, sleep dysfunction and sexual dysfunction, comprising the step of:

providing to the subject suffering from said condition, a therapeutically effective amount of a compound of formula I



wherein

R^1 is a straight-chained alkyl of 1 to 6 carbon atoms, or a branched chain alkyl of 3 to 8 carbon atoms; and

R^2 is phenyl, naphthyl, anthracyl, phenanthryl, pyridyl, pyrimidyl, triazinyl, furyl, pyrrolyl, pyrazolyl, indolyl, imidazolyl, benzofuryl, benzothienyl, oxazolyl, or thiazolyl each optionally substituted with 0 to 3 substituents selected from straight-chain alkyl of 1 to 6 carbon atoms, branched-chain alkyl of 3 to 8 carbon atoms, alkoxy of 1 to 6 carbon atoms, mono- or dialkylamino of 1 to 6 carbon atoms, nitro, halo, amino, cyano, trifluoromethyl, trifluoromethoxy and hydroxy;

or a pharmaceutically acceptable salt thereof.

Claims 27 to 32 (*cancelled*)

33. *(previously presented)* A method according to claim 26, wherein said subject is a human.
34. *(previously presented)* A method according to claim 26, wherein R¹ is a straight-chained alkyl of 1 to 3 carbon atoms, or a branched chain alkyl of 3 to 6 carbon atoms.
35. *(previously presented)* A method according to claim 26, wherein R¹ is a straight-chained alkyl of 1 or 2 carbon atoms.
36. *(previously presented)* A method according to claim 26, wherein R² is phenyl, naphthyl, pyridyl, pyrimidyl, furyl, pyrrolyl, pyrazolyl, indolyl, imidazolyl, benzofuryl, or benzothienyl; each optionally substituted with 1 to 3 substituents the same or different selected from straight-chain alkyl of 1 to 3 carbon atoms, branched-chain alkyl of 3 to 6 carbon atoms, alkoxy of 1 to 3 carbon atoms, mono- or dialkylamino in which each alkyl group has 1 to 3 carbon atoms, nitro, amino, cyano, halogen, trifluoromethyl, trifluoromethoxy, and hydroxy.
37. *(previously presented)* A method according to claim 26, wherein R² is phenyl, naphthyl, pyridyl, pyrrolyl, indolyl, or benzothienyl; each optionally substituted with 1 to 3 substituents the same or different selected from nitro, amino, cyano, halogen, trifluoromethyl, trifluoromethoxy, and hydroxy.
38. *(previously presented)* A method according to claim 26, wherein R² is trifluoromethylphenyl or methoxyphenyl.
39. *(previously presented)* A method according to claim 26, wherein the R¹O substituent is bonded to the 1,4-benzodioxan nucleus at the 8 position.

40. *(previously presented)* A method according to claim 26, wherein R¹ is a straight-chained alkyl of 1 to 3 carbon atoms, or a branched chain alkyl of 3 to 6 carbon atoms and R² is phenyl, naphthyl, pyridyl, pyrimidyl, furyl, pyrrolyl, pyrazolyl, indolyl, imidazolyl, benzofuryl, or benzothienyl; each optionally substituted with 0 to 3 substituents selected from straight-chain alkyl of 1 to 3 carbon atoms, branched-chain alkyl of 3 to 6 carbon atoms, alkoxy of 1 to 3 carbon atoms, mono- or di-alkylamino in which each alkyl group has 1 to 3 carbon atoms, halogen, trifluoromethyl, trifluoromethoxy, and hydroxy.
41. *(previously presented)* A method according to claim 26, wherein R¹ is a straight-chained alkyl of 1 or 2 carbon atoms, and R² is phenyl, naphthyl, pyridyl, pyrrolyl, indolyl, or benzothienyl; each optionally substituted with a 0 to 3 substituents selected from nitro, amino, cyano, halogen, trifluoromethyl, trifluoromethoxy, and hydroxy.
42. *(previously presented)* A method according to claim 26, wherein R¹ is a straight chain alkyl of 1 or 2 carbon atoms and R² is trifluoromethylphenyl or methoxyphenyl.
43. *(previously presented)* A method according to claim 26, wherein said compound is (S)-8-(8-ethoxy-2,3-dihydrobenzo-[1,4]dioxin-2-ylmethyl)-3-naphthalen-2-yl-8-aza-bicyclo[3.2.1] octan-3-ol or a pharmaceutically acceptable salt thereof.
43. *(previously presented)* A method according to claim 26, wherein said compound is (S)-8-(8-ethoxy-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-3-phenyl-8-aza-bicyclo[3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.
44. *(previously presented)* A method according to claim 26, wherein said compound is (S)-3-benzo[b]thiophen-3-yl-8-(8-ethoxy-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-8-aza-bicyclo[3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.

45. *(previously presented)* A method according to claim 26, wherein said compound is 8-
{[(2S)-8-ethoxy-2,3-dihydrobenzo-[1,4]dioxin-2-yl)methyl]-3-pyridin-2-yl-8-aza-
bicyclo [3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.
46. *(previously presented)* A method according to claim 26, wherein said compound is 8-
{[(2S)-8-ethoxy-2,3-dihydrobenzo-[1,4]dioxin-2-yl)methyl]-3-(3-trifluoromethyl-
phenyl)-8-aza-bicyclo[3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.
47. *(previously presented)* A method according to claim 26, wherein said compound is 8-
{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-3-(2-methoxyphenyl)-
8-azabicyclo[3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.
48. *(previously presented)* A method according to claim 26, wherein said compound is 8-
{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-3-[3-
(trifluoromethyl)phenyl]-8-azabicyclo[3.2.1]octan-3-ol or a pharmaceutically
acceptable salt thereof.
49. *(previously presented)* A method according to claim 26, wherein said compound is 8-
{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-3-(2-pyridinyl)-8-
azabicyclo[3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.
50. *(previously presented)* A method according to claim 26, wherein said compound is 3-
(1-benzothien-3-yl)-8-{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-
8-azabicyclo[3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.
51. *(previously presented)* A method according to claim 26, wherein said compound is 8-
{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-3-phenyl-8-
azabicyclo[3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.

DOCKET NO.: AM100299 CON US/WYNC-0677

PATENT

Application No.: 10/663,533

Office Action Dated: April 14, 2004

52. *(previously presented)* A method according to claim 26, wherein said compound is 3-((2S)-8-methoxy-2,3-dihydrobenzo- [1,4]dioxin-2-ylmethyl)-8-naphthalen-2-yl-3-azabicyclo[3.2.1]octan-8-ol or a pharmaceutically acceptable salt thereof.